Danaher Corporation (DHR)

Over the past six months, Danaher's stock has experienced fluctuations, with a closing price of $216.61 as of February 6, 2026. The stock was down 4.33% over the past 12 months, but up 1.53% over the past 30 days. Key events impacting the stock include the Q4 2025 earnings report, which surpassed Wall Street's expectations but led to a stock decrease, full-year 2025 results with a revenue of $24.6 billion, and 2026 guidance projecting core revenue growth of 3%-6%. There was also significant insider selling of Danaher stock in November 2025.

Danaher's products and services exhibit some demand seasonality and market-specific influences. Diagnostic platforms benefit from an active respiratory season, while demand for bioprocessing consumables remains robust. Demand from academic and government research funding has been muted but stable. Changes in China's volume-based procurement have impacted diagnostics performance, though this is expected to moderate in 2026. The company's cost of sales demonstrates a fluctuating pattern with some seasonality, and inventory levels have shown minor fluctuations. The Life Sciences segment's growth can be dependent on the capital expenditure of its end customers, which has been reserved.

Danaher Corp. is a global science and technology innovator focused on improving human health, operating primarily within the healthcare sector, specifically in the life sciences and diagnostics industries. Danaher's business is structured around three core segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance and integrate the development and manufacture of therapeutics. The Life Sciences segment offers research tools used by scientists to study the basic building blocks of life, identify disease causes, develop new therapies, and test and manufacture new drugs, vaccines, and gene-editing technologies. The Diagnostics segment develops instruments, consumables, software, and services for diagnosing diseases. In late 2023, Danaher divested its Environmental & Applied Solutions group, Veralto, to focus primarily on scientific instruments and consumables in the life sciences and diagnostic industries.

Danaher Corporation designs, manufactures, and markets its products and services in the United States, China, and internationally. The company has observed low single-digit core revenue growth in developed markets, with North America slightly up and Western Europe showing a high single-digit increase. High-growth markets, particularly China, have experienced a mid-single-digit decline, influenced by volume-based procurement and reimbursement changes in diagnostics, although growth in biotechnology and life sciences in China has partially offset this.

Danaher maintains a strong brand reputation, reinforced by its focus on innovation and strategic growth. The company has received positive recognition, including being listed among "America's Best Companies" (2026), "Most Trusted Companies in America" (2025), and "Global 2000: United States" (2025) by Forbes. Key events contributing to its reputation include positive responses to new products, the acquisition of Abcam plc, a partnership with AstraZeneca to scale precision medicine, and overwhelmingly positive analyst sentiment.

Danaher Corporation is predominantly owned by institutional shareholders (81.01%), with insiders holding 25.90% and retail investors holding 0.00%. Steven M. Rales is the largest individual shareholder, owning 93.13 million shares, representing 13.18% of the company, followed by Mitchell P. Rales, who owns 83.79 million shares, representing 11.86% of the company. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp.